GlassScriptPhysician profile
Farah Husain
NPI 1639303308
$5,195.07
in general payments reported to CMS, 2019-2025
34 companies · $1,461 in 2025
The $1,461 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $374 · 2022: $715 · 2023: $1,037 · 2024: $1,608 · 2025: $1,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,106.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $729.92 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $457.33 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $443.19 | 2022-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $360.27 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Mannkind Corporation | $353.58 | 2022-2025 | Afrezza |
| Tandem Diabetes Care, INC. | $287.65 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $254.92 | 2022-2025 | Cequr Simplicity |
| Amgen INC. | $220.20 | 2022-2025 | Evenity, Prolia |
| Corcept Therapeutics | $198.03 | 2022-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $180.01 | 2021-2024 | |
| Radius Health, INC. | $171.00 | 2023-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.10 | 2022-2025 | Jardiance |
| Amneal Pharmaceuticals LLC | $144.54 | 2021-2025 | Unithroid |
| Sequel Med Tech, LLC | $134.26 | 2025 | Twiist |
| Dexcom, INC. | $117.02 | 2023-2025 | Dexcom G6 Transmitter |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $111.87 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Ibsa Pharma INC. | $104.44 | 2021-2024 | Tirosint, Licart, Licart |
| Bayer Healthcare Pharmaceuticals INC. | $95.54 | 2021-2025 | |
| Insulet Corporation | $83.26 | 2022-2025 | Omnipod |
| Abbvie INC. | $77.78 | 2022-2025 | |
| Beta Bionics, INC. | $76.20 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amarin Pharma, INC. | $59.50 | 2021-2022 | |
| Amryt Pharma Holdings LTD | $59.07 | 2022-2023 | Mycapssa |
| Antares Pharma, INC. | $52.64 | 2024 | Xyosted |
| Zealand Pharma US, INC. | $50.02 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $43.08 | 2021 | |
| Ascensia Diabetes Care US INC. | $37.92 | 2025 | |
| Madrigal Pharmaceuticals | $27.20 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $23.31 | 2022 | |
| Chiesi USA, INC. | $21.98 | 2025 | Mycapssa |
| Soleno Therapeutics, INC. | $21.68 | 2025 | Vykat Xr |
| Amphastar Pharmaceuticals, INC. | $18.70 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $16.31 | 2024 | Imcivree |
| Ascendis Pharma Endocrinology INC | $15.55 | 2025 | Yorvipath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farah Husain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.